MedTrace Logo

Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

NCT05889949 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-06-07

No results posted yet for this study

Summary

The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Conditions

  • Radiomics
  • Hepatocellular Carcinoma (HCC)
  • Transcatheter Arterial Chemoembolization (TACE)
  • Microvascular Invasion (MVI)
  • Multi-kinase Inhibitors (MKI)

Interventions

DRUG

Sorafenib

oral sorafenib

DRUG

Lenvatinib

oral lenvatinib

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2023-05-31
Completion
2023-05-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889949 on ClinicalTrials.gov